Mineralys Insider Realizes $557K Options Gain Before FDA Date
David Malcom Rodman, the chief medical officer at Mineralys Therapeutics (MLYS), executed a stock options transaction worth $557,000 under a pre-established Rule 10b5-1 trading plan. The sale occurred ahead of an anticipated December FDA decision on one of its drug candidates.
Tickers: $MLYS
Topics: executive activity SEC filing stock sale